Medical device maker ClearStream Technologies Group PLC (AIM: CTN) said it received approval to extend the shelf life of its Intrepide drug eluting stent to 36 months from 12 months.
The company said its testing and certification body KEMA informed it that KEMA has granted CE Mark approval for the shelf-life extension.
The Intrepide stent uses anti-proliferative and anti-inflammatory drug Trapidil as its active agent. Unlike the cytotoxic or cytostatic drugs used on the majority of other DESs, Trapidil is highly stable enabling this significant extension to the Intrepide's shelf-life. The majority of other DESs have a shelf-life of 12 months or less, Clearstream said.www.proactiveinvestors.co.uk
No comments:
Post a Comment